Evaluation of changes in price, volume and expenditure of PD-1 drugs following the government reimbursement negotiation in China: a multiple-treatment period interrupted time series analysis
Journal of Global Health · 2025
DOI: 10.7189/jogh.15.04069 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Global Health, 2025. Verfasst von Hongbin Yi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China. Hauptthemen laut MEDLINE: Health Expenditures, Drug Costs, Reimbursement Mechanisms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Government reimbursement negotiation (GRN) is an important policy tool to increase the accessibility of drugs. In China, the impact of GRN implementation on programmed death-1 (PD-1) drugs price, procurement volume, and expenditure is unknown.
Methods
This study used a multiple-treatment period interrupted time series design covering the period from the first-time recorded in Chinese Medical Economic Information database to 2022 to examine changes in hospital procurement price, volume and expenditure of PD-1 drugs after the implementation of GRN in China. Data were obtained from 698 public hospitals of 30 provinces in China.
Results
A total of four PD-1 drugs have been selected in the National Reimbursement Drug List via GRN between March 2019 and 2022. After the implementation of the first-time GRN, the prices of all PD-1 drugs decreased significantly, with Camrelizumab experiencing the largest reduction in price and the largest increase in volume and expenditure. The Camrelizumab's price decreased by 1151.75 Chinese Yuan (CNY) (β2 = -1151.75; 95% confidence interval (CI) = -1254.534, 1048.96), volume increased by 159.549 thousand defined daily doses (β2 = 159.549; 95% CI = 119.12, 199.979) and expenditure increased by 11.172 million CNY (β2 = 11.172; 95% CI = 1.653, 20.692). Following the implementation of the second-time of GRN, Sintilimab showed the largest decrease in price, with price decreased by 164.099 CNY (β4 = -164.099; 95% CI = -171.867, 156.331), Tislelizumab had the largest increase in volume and expenditure, with the volume increased by 102.185 thousand defined daily doses (β4 = 102.185; 95% CI = 47.862, 156.509) and expenditure increased by 4.119 million CNY (β4 = 4.119; 95% CI = -3.808, 12.047).
Conclusions
The GRN policy improved the accessibility and affordability of PD-1 drugs. Health insurance policy-makers need to consider the legitimate interests of PD-1 drug manufacturers while ensuring the sustainability of the basic health insurance fund.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.
- International Research Centre for Medicinal Administration, Peking University, Beijing, China.
- Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, China.
- Science and Technology Development Centre, Chinese Pharmaceutical Association, Beijing, China.
- Institute for Hospital Management, Tsinghua University, Beijing, China.
Zitieren
APA
Yi, H., Cai, M., Wei, X., Cao, Y., Kuai, L., Xu, D., Qiu, Y., & Han, S. (2025). Evaluation of changes in price, volume and expenditure of PD-1 drugs following the government reimbursement negotiation in China: a multiple-treatment period interrupted time series analysis. Journal of Global Health. https://doi.org/10.7189/jogh.15.04069
Vancouver
Yi H, Cai M, Wei X, Cao Y, Kuai L, Xu D, et al. Evaluation of changes in price, volume and expenditure of PD-1 drugs following the government reimbursement negotiation in China: a multiple-treatment period interrupted time series analysis. Journal of Global Health. 2025. doi:10.7189/jogh.15.04069
BibTeX
@article{Yi2025,
author = {Yi, Hongbin and Cai, Mengtian and Wei, Xiaoxia and Cao, Yingdan and Kuai, Liping and Xu, Dongyan and Qiu, Yue and Han, Sheng},
title = {Evaluation of changes in price, volume and expenditure of PD-1 drugs following the government reimbursement negotiation in China: a multiple-treatment period interrupted time series analysis},
journal = {Journal of Global Health},
year = {2025},
doi = {10.7189/jogh.15.04069}
}
EUVIMED